Allergan antes up $90M in a CRISPR/Cas9 collaboration with Editas on eye diseases – Endpoints News
Endpoints News |
Allergan antes up $90M in a CRISPR/Cas9 collaboration with Editas on eye diseases
Endpoints News The biotech struck a deal to partner with CRISPR/Cas9 leader Editas $EDIT on up to five programs aimed at curing eye diseases. And the package includes Editas' lead program for Leber Congenital Amaurosis (LCA10), which is currently wrapping preclinical … Allergan (AGN), Editas Medicine (EDIT) Enter Alliance to Discover and Develop CRISPR Genome Editing Medicines … Allergan, Editas partner on CRISPR tech in eye diseases First Trial in Sight, Editas Cuts $90M Eye Drug Deal With Allergan |
